GH Research (GHRS) Common Equity (2021 - 2026)
GH Research (GHRS) posted quarterly Common Equity of $279.7 million for Q4 2025, up 56.3% year-over-year from $179.0 million in Q4 2024, and down 4.01% quarter-over-quarter from $291.4 million in Q3 2025.
GH Research (GHRS) Common Equity (2021 - 2026) Analysis & Trends
GH Research's Common Equity history runs 5 years deep, the most recent figure standing at $279.7 million for Q4 2025.
- In Q4 2025, Common Equity rose 56.3% year-over-year to $279.7 million; the TTM figure through Dec 2025 stood at $279.7 million (up 56.3% YoY), while the FY2025 annual figure was $279.7 million, up 56.3% from the prior year.
- Common Equity for Q4 2025 stood at $279.7 million, down from $291.4 million in the prior quarter.
- The five-year high for Common Equity was $310.2 million in Q1 2025, with the low at $179.0 million in Q4 2024.
- The 5-year median for Common Equity is $253.3 million (2022), against an average of $248.9 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity retreated 18.28% in 2024, then soared 56.3% in 2025.
- GH Research's Common Equity stood at $277.2 million in 2021, then slipped by 9.87% to $249.8 million in 2022, then dropped by 12.35% to $219.0 million in 2023, then slipped by 18.28% to $179.0 million in 2024, then jumped by 56.3% to $279.7 million in 2025.
- Business Quant data shows GHRS's Common Equity at $279.7 million in Q4 2025, $291.4 million in Q3 2025, and $303.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | 359.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 359.49 Mn |
| Dec 31, 2025 | 279.70 Mn |
| Sep 30, 2025 | 291.40 Mn |
| Jun 30, 2025 | 303.18 Mn |
| Mar 31, 2025 | 310.21 Mn |
| Dec 31, 2024 | 178.95 Mn |
| Sep 30, 2024 | 189.37 Mn |
| Jun 30, 2024 | 198.68 Mn |
| Mar 31, 2024 | 209.75 Mn |
| Dec 31, 2023 | 218.97 Mn |
| Sep 30, 2023 | 225.77 Mn |
| Jun 30, 2023 | 232.98 Mn |
| Mar 31, 2023 | 241.83 Mn |
| Dec 31, 2022 | 249.82 Mn |
| Sep 30, 2022 | 256.74 Mn |
| Jun 30, 2022 | 263.22 Mn |
| Mar 31, 2022 | 269.48 Mn |
| Dec 31, 2021 | 277.18 Mn |
| Sep 30, 2021 | 283.60 Mn |